- Home
- NAAS vs IMRN Comparison
NAAS vs IMRN Comparison
Compare NAAS & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- IMRN
- Stock Information
- Founded
- NAAS 2019
- IMRN 1994
- Country
- NAAS China
- IMRN Australia
- Employees
- NAAS N/A
- IMRN N/A
- Industry
- NAAS Other Specialty Stores
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- IMRN Health Care
- Exchange
- NAAS Nasdaq
- IMRN Nasdaq
- Market Cap
- NAAS 8.3M
- IMRN 9.2M
- IPO Year
- NAAS 2017
- IMRN N/A
- Fundamental
- Price
- NAAS $2.75
- IMRN $1.90
- Analyst Decision
- NAAS
- IMRN Strong Buy
- Analyst Count
- NAAS 0
- IMRN 1
- Target Price
- NAAS N/A
- IMRN $5.00
- AVG Volume (30 Days)
- NAAS 142.5K
- IMRN 55.1K
- Earning Date
- NAAS 09-05-2025
- IMRN 08-29-2025
- Dividend Yield
- NAAS N/A
- IMRN N/A
- EPS Growth
- NAAS N/A
- IMRN N/A
- EPS
- NAAS N/A
- IMRN N/A
- Revenue
- NAAS $27,534,354.00
- IMRN $4,777,422.00
- Revenue This Year
- NAAS $378.49
- IMRN N/A
- Revenue Next Year
- NAAS N/A
- IMRN N/A
- P/E Ratio
- NAAS N/A
- IMRN N/A
- Revenue Growth
- NAAS N/A
- IMRN 48.63
- 52 Week Low
- NAAS $1.96
- IMRN $1.50
- 52 Week High
- NAAS $74.40
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- NAAS 44.36
- IMRN 60.10
- Support Level
- NAAS $3.04
- IMRN $1.73
- Resistance Level
- NAAS $3.85
- IMRN $1.85
- Average True Range (ATR)
- NAAS 0.32
- IMRN 0.10
- MACD
- NAAS -0.00
- IMRN 0.01
- Stochastic Oscillator
- NAAS 5.31
- IMRN 100.00
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.